Viking Global Investors LP and Affiliates' Ownership in Oruka Therapeutics, Inc.

Viking Global Investors LP and its affiliates have filed a Schedule 13G to report their ownership in Oruka Therapeutics, Inc. The filing indicates that Viking Global Investors LP, along with its related entities, beneficially owns a significant portion of Oruka Therapeutics' common stock. Specifically, Viking Global Investors LP owns 2,666,690 shares, representing 5.5% of the outstanding shares. Other entities, including Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, and Viking Global Opportunities Portfolio GP LLC, also hold substantial positions. The filing also includes details on the shared voting and dispositive power of these entities. The report is based on the outstanding shares following a private placement that closed on September 19, 2025. The filing is made pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934.